Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic and predictive value of MET deregulation in non-small cell lung cancer.

1 Apr 2015

Abstract excerpt

Recent progress in cancer biology has led to the discovery of increasing number of oncogene alterations that have dramatically changed the paradigm of lung cancer treatment. MET is a tyrosine kinase receptor for the hepatocyte growth factor (HGF) that is deregulated in several malignancies, including non-small cell lung cancer (NSCLC). Abnormal MET-HGF signaling pathway activation can occur via different...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Liver Disease Diagnosis and Treatment
Share to Liver physiology and pathology
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25992382
DOI: 10.3978/j.issn.2305-5839.2015.03.43

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic and predictive value of MET deregulation in non-small cell lung cancer.PMID 25992382Read ↗

MET as a possible target for non-small-cell lung cancer.Semantic proximity Read ↗

MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.Semantic proximity Read ↗

The METeoric rise of MET in lung cancerSemantic proximity Read ↗

Met inhibitors in the treatment of lung cancer: the evidence to date.Semantic proximity Read ↗

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.Semantic proximity Read ↗

MET and Small-Cell Lung CancerSemantic proximity Read ↗

MET Activation in Lung Cancer and Response to Targeted TherapiesSemantic proximity Read ↗

MET: a new promising biomarker in non-small-cell lung carcinoma.Semantic proximity Read ↗

The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.Semantic proximity Read ↗

Targeting mesenchymal-epithelial transition factor signaling in cancer: from genetic alterations to clinical advances and future prospects.Semantic proximity Read ↗

The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies.Semantic proximity Read ↗

Expression and mutational analysis of MET in human solid cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.